Gaucher is caused by a deficiency of an enzyme called glucocerebrosidase (also known as acid beta-glucosidase), which is needed to break down a fatty substance called glucocerebroside. When this enzyme is missing or does not work properly, glucocerebroside builds up inside cells, particularly in the spleen, liver, bone marrow and, in some types of Gaucher disease, the brain.
Gaucher disease is a rare inherited lysosomal storage disorder. There are three recognised types of Gaucher disease, which are classified according to whether and how the nervous system is affected.
Read on for information about the condition or see the latest updates and resources.
Frequently asked questions
The condition is inherited in an autosomal recessive pattern. This means that a child must inherit an altered copy of the responsible gene from both parents in order to develop Gaucher disease.
Symptoms and severity vary considerably between individuals, even among members of the same family, but may include:
Enlarged spleen (splenomegaly)
Enlarged liver (hepatomegaly)
Low platelet count, leading to easy bruising or bleeding
Anaemia and fatigue
Bone pain and bone crises
Reduced bone density and increased risk of fractures
Delayed growth in children
Joint problems and reduced mobility
There are three recognised types of Gaucher disease, which are classified according to whether and how the nervous system is affected.
Type 1 Gaucher disease is the most common form and is sometimes referred to as the non-neuronopathic form because it does not directly affect the brain or central nervous system.
Symptoms can begin at any age, from childhood through to adulthood, and vary greatly in severity. People with Type 1 Gaucher disease may experience:
Enlarged spleen and liver
Anaemia and fatigue
Low platelet count
Easy bruising and bleeding
Bone pain
Osteoporosis and fractures
Growth delays in children
Many individuals with Type 1 Gaucher disease respond well to disease-specific treatments, including enzyme replacement therapy (ERT) and substrate reduction therapy (SRT), which can help manage symptoms and improve quality of life.
Type 2 Gaucher disease is the acute neuronopathic form of the condition. It is a rare and severe form that affects both the body and the central nervous system.
Symptoms usually begin in infancy and may include:
Severe neurological involvement
Difficulty swallowing and feeding
Abnormal eye movements
Muscle rigidity
Developmental difficulties
Enlargement of the liver and spleen
Type 2 Gaucher disease progresses rapidly and currently available treatments do not prevent the neurological aspects of the condition. Management focuses on symptom control, supportive care and improving quality of life for affected children and their families.
Type 3 Gaucher disease is known as the chronic neuronopathic form. Like Type 2, it affects the nervous system, but progression is generally slower and symptoms develop over a longer period.
People with Type 3 Gaucher disease may experience:
Enlargement of the liver and spleen
Bone disease and bone pain
Low blood counts
Difficulties with eye movements
Seizures in some individuals
Learning and developmental difficulties
Other neurological symptoms that can worsen over time
The severity and progression of Type 3 Gaucher disease can vary significantly between individuals. Treatments such as enzyme replacement therapy can improve many of the non-neurological symptoms, although they do not stop the progression of neurological disease.
Although Gaucher disease is a lifelong condition, advances in diagnosis, specialist care and treatment have greatly improved outcomes for many people living with the disease. Regular monitoring by an experienced multidisciplinary team is important to help manage symptoms and maintain overall health and wellbeing.
Support from MPS Society and the Gaucher Association
The MPS Society works in partnership with the Gaucher Association to provide support for people living with Gaucher disease and their families.
The Gaucher Association remains the primary source of Gaucher-specific information, resources, events and activities. Alongside this, the MPS Society Support Team is available to offer additional emotional, practical and peer support to individuals and families affected by the condition.
Need someone to talk to?
Our support includes an active listening service and telephone helpline.
Latest updates
Generation Study update: implications for our expanded UK newborn screening panel work
We wanted to share an important update with our community about the Generation Study and what the completion of this research programme means for the future of newborn screening.